# Association Between Serum IL-6 Levels and Disease Severity Among COVID-19 Patients Hospitalized at a Tertiary Care Hospital in Bangladesh

**Authors:** Sadia Amin, Nisat Zabin, Noureen Amin, Sheikh Nazmul Islam, Taiyeb I Zahangir, Sumona Islam, Mahnaz Islam, Amit Bari

PMC · DOI: 10.7759/cureus.102631 · Cureus · 2026-01-30

## TL;DR

The study finds that higher IL-6 levels in hospitalized COVID-19 patients are linked to more severe disease, suggesting IL-6 could help identify high-risk patients early.

## Contribution

This study identifies serum IL-6 as an independent predictor of severe or critical COVID-19 outcomes in a Bangladeshi patient population.

## Key findings

- Higher IL-6 levels were significantly associated with severe or critical disease severity.
- IL-6 levels above 14 pg/mL independently predicted severe or critical illness.
- IL-6 correlated with markers like CRP, ferritin, and D-dimer, and inversely with lymphocyte count.

## Abstract

Introduction

COVID-19 severity varies widely among patients, and early identification of those at risk for severe disease is essential. IL-6, a key inflammatory cytokine, has been implicated in the pathogenesis of severe COVID-19. This study aimed to assess the association between serum IL-6 levels and disease severity among hospitalized COVID-19 patients at Bangabandhu Sheikh Mujib Medical University (BSMMU).

Methodology

A cross-sectional study was conducted among 90 RT-PCR-confirmed COVID-19 patients admitted to BSMMU. Patients were categorized into non-severe, severe, and critical groups based on WHO guidelines. Serum IL-6 levels and routine laboratory parameters were measured. Statistical analyses included chi-square tests, correlation analysis, logistic regression, and ROC curve evaluation to determine predictors of severity.

Results

Higher IL-6 levels were significantly associated with increasing disease severity. Severe and critical patients were older and more likely to have diabetes or hypertension. IL-6 showed positive correlations with neutrophil count, CRP, ferritin, D-dimer, and lactate dehydrogenase (LDH), and a negative correlation with lymphocyte count. Logistic regression identified IL-6 >14 pg/mL as an independent predictor of severe or critical disease. Receiver operating characteristic (ROC) analysis demonstrated excellent diagnostic performance of IL-6 in predicting severe outcomes.

Conclusion

Elevated IL-6 levels correlate strongly with COVID-19 severity and independently predict severe or critical illness. IL-6 may serve as an effective biomarker for early risk stratification, enabling timely intervention and improved patient management. Further studies are recommended to validate these findings and explore IL-6-targeted therapies.

## Linked entities

- **Proteins:** IL6 (interleukin 6)
- **Diseases:** COVID-19 (MONDO:0100096), diabetes (MONDO:0005015)

## Full-text entities

- **Genes:** CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, REN (renin) [NCBI Gene 5972] {aka ADTKD4, HNFJ2, RTD}, ACE2 (angiotensin converting enzyme 2) [NCBI Gene 59272] {aka ACEH}
- **Diseases:** CKD (MESH:D012080), dyspnea (MESH:D004417), infected (MESH:D007239), Ischemic heart disease (MESH:D017202), COVID (MESH:D000086382), DM (MESH:D003920), cough (MESH:D003371), Chronic kidney disease (MESH:D051436), rheumatological diseases (MESH:D012216), chronic inflammation (MESH:D007249), rheumatoid arthritis (MESH:D001172), critical illness (MESH:D016638), HTN (MESH:D006973), sore throat (MESH:D010612), neutrophilia (MESH:C563010), glucose dysregulation (MESH:D018149), fever (MESH:D005334), ARDS (MESH:D012128), systemic lupus erythematosus (MESH:D008180), infectious illness (MESH:D003141), hypoxemia (MESH:D000860), respiratory failure (MESH:D012131), bacterial infection (MESH:D001424), multi-organ failure (MESH:D009102), chronic lung disease (MESH:D029424), fatigue (MESH:D005221), cardiac disease (MESH:D006331), pneumonia (MESH:D011014)
- **Chemicals:** nicotine (MESH:D009538), oxygen (MESH:D010100), tocilizumab (MESH:C502936)
- **Species:** Homo sapiens (human, species) [taxon 9606], Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12950192/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12950192/full.md

## References

25 references — full list in the complete paper: https://tomesphere.com/paper/PMC12950192/full.md

---
Source: https://tomesphere.com/paper/PMC12950192